The Volume-Outcome Relationship for TAVR in a U.S. Registry

Increased site experience with transcatheter aortic-valve replacements is associated with better in-hospital outcomes.

More than 500 U.S. hospitals are now performing transcatheter aortic-valve replacement (TAVR), and all are required to report cases and outcomes to the national Society of Thoracic Surgeons/American College of Cardiology's Transcatheter Valve Therapy (TVT) Registry. The present analysis of this registry examines the relationship between site volume and in-hospital outcomes in ≈43,000 commercial procedures performed between November 2011 and November 2015 at 395 sites (NCT01737528).

Comparisons were made based on each site's case sequence, which accounts for each institution's learning curve. In most cases, TAVR was performed electively (91%), with general anesthesia (92%) and a transfemoral approach (71%). Unadjusted in-hospital outcomes inc…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)